176
Participants
Start Date
September 1, 2020
Primary Completion Date
September 1, 2025
Study Completion Date
December 31, 2025
Cytarabine
4 mg/m2/day administered IV day -10 through -9.
Busulfan
3.2 mg/kg/day administered IV day -8 through -6.
Cyclophosphamide
1.8 g/m2/day administered IV day -5 through -4.
Me-CCNU
250mg/m2 once administered orally on day -3.
Rabbit antithymocyte globulin
Between 6mg/kg total dose administered IV day -5 through -2 AND 7.5mg/kg total dose administered IV day -5 through -2.
Allogeneic HSCT
Day 0
Cyclosporin A
2.5 mg/kg/day administered intravenously from day -7, target: 200-300ng/mL. Usually tapered during the second month, and ended in complete withdrawal during the ninth month after transplantation.
Mycophenolate Mofetil
500 mg/day administered intravenously from day -9, ended in complete withdrawal on day +100.
MTX
15 mg/m2 administered intravenously on day +1, 10mg/m2 on day +3, +6, and +9.
RECRUITING
Xiangya Hospital Central South University, Changsha
RECRUITING
Xinqiao Hospital, State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing
RECRUITING
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou
RECRUITING
Zhejiang Provincial People's Hospital, Hangzhou
RECRUITING
The First Affiliated Hospital of Nanjing Medical University, Nanjing
RECRUITING
The Affiliated People's Hospital of Ningbo University, Ningbo
RECRUITING
The First Affiliated Hospital of Ningbo University, Ningbo
RECRUITING
The First Affiliated Hospital of Soochow University, Suzhou
First Affiliated Hospital of Zhejiang University
OTHER